Abstract
Over the last couple of decades, the treatment of psychoses has much advanced; yet, despite all progress, the individual and societal burden associated with psychosis and particularly schizophrenia has largely remained unchanged. Therefore, much hope is currently placed on indicated prevention as a mean to fight these burdens before they set in. Though the number of studies investigating pharmacological interventions is still limited, encouraging results have been reported from the pioneering trials, despite several methodological limitations. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention, but also treatment. In consequence, outcome criteria have to be broadened to cover the current needs of the patients. As is indicated by a recent study successfully using Omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. Treatment studies may become promoted by the proposed introduction of a new disorder category into DSM-V. Future prevention studies, however, need to solve the challenge of changing immediate transition rates, demanding for new risk enrichment strategies as a prerequisite for feasible trial designs.
Keywords: At-risk, early intervention, prevention, psychosis, antipsychotics, antidepressants, omega-3 fatty acids, schizophrenia, DSM-V, sub-psychotic symptoms
Current Pharmaceutical Design
Title: Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis
Volume: 18 Issue: 4
Author(s): Stephan Ruhrmann, Joachim Klosterkotter, Mitja Bodatsch, Andreas Bechdolf, Benno Graf Schimmelmann, Alexandra Nikolaides, Desiree Hilboll and Frauke Schultze-Lutter
Affiliation:
Keywords: At-risk, early intervention, prevention, psychosis, antipsychotics, antidepressants, omega-3 fatty acids, schizophrenia, DSM-V, sub-psychotic symptoms
Abstract: Over the last couple of decades, the treatment of psychoses has much advanced; yet, despite all progress, the individual and societal burden associated with psychosis and particularly schizophrenia has largely remained unchanged. Therefore, much hope is currently placed on indicated prevention as a mean to fight these burdens before they set in. Though the number of studies investigating pharmacological interventions is still limited, encouraging results have been reported from the pioneering trials, despite several methodological limitations. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention, but also treatment. In consequence, outcome criteria have to be broadened to cover the current needs of the patients. As is indicated by a recent study successfully using Omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. Treatment studies may become promoted by the proposed introduction of a new disorder category into DSM-V. Future prevention studies, however, need to solve the challenge of changing immediate transition rates, demanding for new risk enrichment strategies as a prerequisite for feasible trial designs.
Export Options
About this article
Cite this article as:
Ruhrmann Stephan, Klosterkotter Joachim, Bodatsch Mitja, Bechdolf Andreas, Graf Schimmelmann Benno, Nikolaides Alexandra, Hilboll Desiree and Schultze-Lutter Frauke, Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316172
DOI https://dx.doi.org/10.2174/138161212799316172 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Grey Matter Atrophy in Mild Cognitive Impairment / Early Alzheimer Disease Associated with Delusions: A Voxel-Based Morphometry Study
Current Alzheimer Research Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Stereotyped Paroxysmal Psychiatric Symptoms During Oculogyric Crisis or ‘Cognitive Dystonia’: A Case Report
Current Drug Safety Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Amyloid β Peptide Levels Increase in Brain of AβPP Swedish Mice after Exposure to Chlorpyrifos
Current Alzheimer Research Myofascial Temporomandibular Disorder
Current Rheumatology Reviews Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Analytical Methods for Determination of ·NO and ·NO2 and their Applicability in Biological Studies
Current Pharmaceutical Analysis Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Ecto-Nucleotidase Inhibitors: Recent Developments in Drug Discovery
Mini-Reviews in Medicinal Chemistry Blocking the Link between Stimulus and Response at Previously Attended Locations: Evidence for Inhibitory Tagging Mechanism
Neuroscience and Biomedical Engineering (Discontinued)